HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 425 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,948,924 | +30.1% | 155,731 | +22.8% | 0.00% | 0.0% |
| Q2 2023 | $4,572,702 | -72.9% | 126,773 | -57.3% | 0.00% | -66.7% |
| Q4 2022 | $16,899,129 | +19.9% | 296,997 | -16.6% | 0.00% | 0.0% |
| Q3 2022 | $14,089,000 | +70.2% | 356,319 | +89.4% | 0.00% | +50.0% |
| Q2 2022 | $8,277,000 | +2552.9% | 188,124 | +968.1% | 0.00% | – |
| Q4 2019 | $312,000 | +30.0% | 17,613 | +25.9% | 0.00% | – |
| Q2 2019 | $240,000 | +5.7% | 13,988 | -0.7% | 0.00% | – |
| Q1 2019 | $227,000 | -39.0% | 14,083 | -31.3% | 0.00% | – |
| Q3 2018 | $372,000 | -89.6% | 20,502 | -90.4% | 0.00% | -100.0% |
| Q2 2018 | $3,589,000 | +5.4% | 212,738 | +22.4% | 0.00% | 0.0% |
| Q1 2018 | $3,405,000 | +42.0% | 173,836 | +46.9% | 0.00% | 0.0% |
| Q4 2017 | $2,398,000 | -48.4% | 118,376 | -55.9% | 0.00% | 0.0% |
| Q4 2015 | $4,648,000 | +239.0% | 268,195 | +162.7% | 0.00% | – |
| Q3 2015 | $1,371,000 | +26.9% | 102,083 | +20.1% | 0.00% | – |
| Q1 2014 | $1,080,000 | – | 85,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |